Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

Trial Profile

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GIMEMA-ERIC
  • Most Recent Events

    • 12 Oct 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
    • 12 Oct 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.
    • 12 Oct 2018 Planned initiation date changed from 1 Jul 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top